Ultralife Corporation (NASDAQ: ULBI) reported breakeven operating
income and adjusted EBITDA of $1.2 million on revenue of $31.9
million for the first quarter ended March 31, 2023. The operating
results for the first quarter of 2023 were negatively impacted
by the cybersecurity attack announced by the Company on March 2,
2023. For the first quarter of 2022, the Company reported an
operating loss of $0.3 million and adjusted EBITDA of $1.1 million
on revenue of $30.4 million.
As disclosed on March 2, 2023, the Company
discovered a cybersecurity ransomware attack at its Newark, NY and
Virginia Beach, VA locations on January 25, 2023. The attack
impacted our ability to process orders, ship products, provide
services to customers and effectively manage our sales and
operating planning process over a several week period at our
Newark, NY location and an even longer period at our Virginia
Beach, VA location. While production and shipping have been resumed
in both locations, considerable time during the first quarter was
devoted to data restoration, systems recovery, systems security
augmentation and regulatory reporting of the attack. Management
continues to work on its cybersecurity insurance claim covering the
cost of engaging external cybersecurity experts and the business
interruption impact. The Company’s deductible for its
cyber-insurance policy of $0.1 million is included in our first
quarter results. No ransom was paid.
“During the first quarter, while devoting
considerable time and attention to dealing with the aftereffects of
the cybersecurity event, we improved gross margin from the prior
quarter primarily through price realization. Execution of lean
manufacturing initiatives to improve production efficiency,
continued price realization and qualification of alternate
component suppliers to recapture gross margin remain our highest
near-term priorities,” said Mike Manna, President and Chief
Executive Officer. “In addition, we are focused on fulfilling
orders that were held back in the first quarter due to the
cybersecurity attack and meeting surging demand from our medical
and government/defense customers while satisfying ongoing demand
from other commercial end markets, particularly oil & gas. Our
goal for 2023 remains to deliver high-quality, profitable growth
through execution of operational improvements, and to generate
incremental cash flow to pay down our acquisition debt.”
First Quarter 2023 Financial Results
Revenue was $31.9 million, an increase of $1.5
million, or 5.1%, compared to $30.4 million for the first quarter
of 2022. Overall, government/defense sales increased 24.7% while
commercial sales decreased 1.7% compared to the 2022 period.
Battery & Energy Products sales decreased 2.3% to $28.5
million, compared to $29.2 million last year, reflecting the impact
of the cybersecurity attack, primarily related to medical and
government/defense shipments, partially offset by a 21.3% increase
in oil & gas market sales. Communications Systems sales
increased 181.8% to $3.4 million compared to $1.2 million for the
same period last year, primarily attributable to shipments under a
vehicle-amplifier adaptor order with a global defense contractor
received in July 2022, partially offset by the impact of the
cybersecurity attack. Our total backlog exiting the first quarter
was $108.1 million, with $96.1 million due to ship over the
remaining nine months of 2023 representing a 30.2% increase over
the comparable $73.8 million for the same period last year. Total
backlog decreased $2.9 million or 2.6% compared to the backlog
exiting the prior quarter, the highest in the Company’s
history.
Gross profit was $7.4 million, or 23.3% of
revenue, compared to $7.0 million, or 22.9% of revenue, for the
same quarter a year ago. Battery & Energy Products’ gross
margin was 22.9%, compared to 23.1% last year, primarily due to
inefficiencies resulting from the cybersecurity attack as well as
lingering supply chain disruptions including higher material and
logistics costs, and continued investments in the transition of new
products to high volume production, partially offset by improved
price realization. Communications Systems gross margin was 26.8%
compared to 19.4% last year, primarily due to higher factory volume
tempered by inefficiencies associated with the cybersecurity
attack.
Operating expenses were $7.4 million compared to
$7.3 million last year, an increase of 2.2%, reflecting continued
investment in new product development and the recording of the $0.1
million deductible on our cyber-insurance policy for expenses
incurred during the quarter. Operating expenses were 23.2% of
revenue compared to 23.9% of revenue for the year-earlier
period.
Operating income was breakeven for the first
quarter of 2023 compared to an operating loss of $0.3 million last
year.
Net loss was $0.3 million or $0.02 per diluted share, compared
to net loss of $0.2 million or $0.01 per diluted share for the
first quarter of 2022.
Adjusted EBITDA, defined as EBITDA including non-cash,
stock-based compensation expense, was $1.2 million for the first
quarter of 2023 or 3.6% of revenue, compared to $1.1 million or
3.6% of revenue for the year earlier period.
See the “Non-GAAP Financial Measures” section of
this release for a reconciliation of adjusted EBITDA to net income
attributable to Ultralife Corporation.
About Ultralife Corporation
Ultralife Corporation serves its markets with
products and services ranging from power solutions to
communications and electronics systems. Through its engineering and
collaborative approach to problem solving, Ultralife
serves government/defense and commercial customers across the
globe.
Headquartered in Newark, New York, the Company's
business segments include Battery & Energy Products and
Communications Systems. Ultralife has operations in North America,
Europe and Asia. For more information, visit
www.ultralifecorporation.com.
Conference Call Information
Ultralife will hold its first quarter earnings
conference call today at 8:30 AM ET.
To ensure a fast and reliable connection to our
investor conference call, we now require participants dialing in by
phone to register using the following link prior to the call:
https://register.vevent.com/register/BId33ee3ac5fa74d2e946203064e7fb772.
This will eliminate the need to speak with an operator. Once
registered, dial-in information will be provided along with a
personal identification number. Should you register early and
misplace your details, you can simply click back on this same link
at any time to register and view this information again. A live
webcast of the conference call will be available to investors in
the Events & Presentations section of the Company's website at
http://investor.ultralifecorporation.com. For those who cannot
listen to the live broadcast, a replay of the webcast will be
available shortly after the call at the same location.
This press release may contain forward-looking
statements based on current expectations that involve a number of
risks and uncertainties. The potential risks and uncertainties that
could cause actual results to differ materially include the impact
of COVID-19 and related supply chain disruptions, potential
reductions in revenues from key customers, acceptance of our new
products on a global basis and uncertain global economic
conditions. The Company cautions investors not to place undue
reliance on forward-looking statements, which reflect the Company's
analysis only as of today's date. The Company undertakes no
obligation to publicly update forward-looking statements to reflect
subsequent events or circumstances. Further information on these
factors and other factors that could affect Ultralife’s financial
results is included in Ultralife’s Securities and Exchange
Commission (SEC) filings, including the latest Annual Report on
Form 10-K.
ULTRALIFE CORPORATION AND SUBSIDIARIES |
CONSOLIDATED BALANCE SHEETS(Dollars in
Thousands) |
(Unaudited) |
|
|
ASSETS |
|
|
|
|
|
March 31,2023 |
|
December 31,2022 |
Current Assets: |
|
|
|
Cash |
$5,605 |
|
$5,713 |
Trade Accounts Receivable, Net |
24,463 |
|
27,779 |
Inventories, Net |
47,311 |
|
41,192 |
Prepaid Expenses and Other Current Assets |
3,973 |
|
4,304 |
Total Current Assets |
81,352 |
|
78,988 |
|
|
|
|
Property, Plant and Equipment,
Net |
21,412 |
|
21,716 |
Goodwill |
37,518 |
|
37,428 |
Other Intangible Assets,
Net |
15,747 |
|
15,921 |
Deferred Income Taxes,
Net |
12,965 |
|
12,069 |
Other Non-Current Assets |
2,160 |
|
2,308 |
Total Assets |
$171,154 |
|
$168,430 |
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
Current Liabilities: |
|
Accounts Payable |
$18,988 |
|
$16,074 |
Current Portion of Long-Term Debt |
2,000 |
|
2,000 |
Accrued Compensation and Related Benefits |
2,321 |
|
2,890 |
Accrued Expenses and Other Current Liabilities |
5,890 |
|
7,949 |
Total Current Liabilities |
29,199 |
|
28,913 |
Long-Term Debt, Net |
21,126 |
|
19,310 |
Deferred Income Taxes,
Net |
2,456 |
|
1,917 |
Other Non-Current
Liabilities |
1,969 |
|
1,887 |
Total Liabilities |
54,750 |
|
52,027 |
|
|
|
|
Shareholders' Equity: |
|
|
|
Common Stock |
2,057 |
|
2,057 |
Capital in Excess of Par Value |
187,544 |
|
187,405 |
Accumulated Deficit |
(48,297) |
|
(47,951) |
Accumulated Other Comprehensive Loss |
(3,553) |
|
(3,750) |
Treasury Stock |
(21,484) |
|
(21,484) |
Total Ultralife Equity |
116,267 |
|
116,277 |
Non-Controlling Interest |
137 |
|
126 |
Total Shareholders’ Equity |
116,404 |
|
116,403 |
|
|
|
|
Total Liabilities and Shareholders' Equity |
$171,154 |
|
$168,430 |
ULTRALIFE CORPORATION AND SUBSIDIARIES |
CONSOLIDATED STATEMENTS OF INCOME(In
Thousands Except Per Share Amounts) |
(Unaudited) |
|
|
|
Three-Month Period Ended |
|
March 31, |
|
March 31, |
|
2023 |
|
2022 |
Revenues: |
|
|
|
Battery & Energy Products |
$28,470 |
|
$29,150 |
Communications Systems |
3,446 |
|
1,223 |
Total
Revenues |
31,916 |
|
30,373 |
|
|
|
|
Cost of Products
Sold: |
|
|
|
Battery & Energy Products |
21,958 |
|
22,429 |
Communications Systems |
2,522 |
|
986 |
Total Cost of Products
Sold |
24,480 |
|
23,415 |
|
|
|
|
Gross Profit |
7,436 |
|
6,958 |
|
|
|
|
Operating
Expenses: |
|
|
|
Research and Development |
2,032 |
|
1,857 |
Selling, General and Administrative |
5,378 |
|
5,396 |
Total Operating
Expenses |
7,410 |
|
7,253 |
|
|
|
|
Operating Income
(Loss) |
26 |
|
(295) |
|
|
|
|
Other
Expense |
(494) |
|
(117) |
Loss Before Income Tax
Provision |
(468) |
|
(412) |
|
|
|
|
Income Tax Benefit |
(133) |
|
(251) |
|
|
|
|
Net Loss |
(335) |
|
(161) |
|
|
|
|
Net Income Attributable to
Non-Controlling Interest |
(11) |
|
(7) |
|
|
|
|
Net Loss Attributable
to Ultralife Corporation |
($346) |
|
($168) |
|
|
|
|
Net Loss Per Share
Attributable to Ultralife Common Shareholders – Basic |
($0.02) |
|
($0.01) |
|
|
|
|
Net Loss Per Share
Attributable to Ultralife Common Shareholders –
Diluted |
($0.02) |
|
($0.01) |
|
|
|
|
Weighted Average Shares
Outstanding – Basic |
16,135 |
|
16,104 |
|
|
|
|
Weighted Average Shares
Outstanding – Diluted |
16,135 |
|
16,104 |
Adjusted EBITDA
In evaluating our business, we consider and use
adjusted EBITDA, a non-GAAP financial measure, as a supplemental
measure of our operating performance in addition to GAAP financial
measures. We define adjusted EBITDA as net income (loss)
attributable to Ultralife Corporation before net interest expense,
provision (benefit) for income taxes, depreciation and
amortization, and stock-based compensation expense, plus/minus
expense/income that we do not consider reflective of our ongoing
continuing operations. We reconcile adjusted EBITDA to net income
(loss) attributable to Ultralife Corporation, the most comparable
financial measure under GAAP. Neither current nor potential
investors in our securities should rely on adjusted EBITDA as a
substitute for any GAAP measures and we encourage investors to
review the following reconciliation of adjusted EBITDA to net
income (loss) attributable to Ultralife Corporation.
ULTRALIFE CORPORATION AND
SUBSIDIARIESCALCULATION OF ADJUSTED
EBITDA(Dollars in
Thousands)(Unaudited) |
|
|
Three-Month Period Ended |
|
March 31, 2023 |
|
March 31, 2022 |
|
|
|
|
Net Loss Attributable to
Ultralife Corporation |
($346) |
|
($168) |
Adjustments: |
|
|
|
Interest Expense, Net |
424 |
|
134 |
Income Tax Benefit |
(133) |
|
(251) |
Depreciation Expense |
762 |
|
816 |
Amortization of Intangible Assets |
209 |
|
328 |
Stock-Based Compensation Expense |
139 |
|
189 |
Non-Recurring – Cyber Insurance Deductible |
100 |
|
- |
Non-Cash Purchase Accounting Adjustment |
- |
|
55 |
Adjusted EBITDA |
$1,155 |
|
$1,103 |
Company Contact:Ultralife
CorporationPhilip A. Fain(315)
210-6110pfain@ulbi.com |
Investor Relations Contact:LHA Jody
Burfening(212)
838-3777jburfening@lhai.com |
Ultralife (NASDAQ:ULBI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ultralife (NASDAQ:ULBI)
Historical Stock Chart
From Apr 2023 to Apr 2024